TerminatedNCT03669640

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Medication studyAges 18–55Multiple countries

The study in practice

Understand this study

This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Listed locations: Bellflower and 44 more locationsSee all locations and recruitment
Study phase: Phase 2

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: December 4, 2018

Recruitment status: Terminated
Enrollment listed in the registry: 131
Sponsor: Hoffmann-La Roche
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States, Japan, Spain, ...
Age range: From 18 Years to 55 Years
Official registry ID: NCT03669640
Official title: Show the full official title
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Terminated

Bellflower, United States · Garden Grove, United States · Glendale, United States

40 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Hoffmann-La Roche.

Does this study involve medication?

Yes. The study involves medication, including RO6889450 and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.